Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) EV-to-Revenue : 8.75 (As of May. 16, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Panacea Life Sciences Holdings's enterprise value is $24.18 Mil. Panacea Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2.76 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-Revenue for today is 8.75.

The historical rank and industry rank for Panacea Life Sciences Holdings's EV-to-Revenue or its related term are showing as below:

PLSH' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.27 Med: 10.66 Max: 15.15
Current: 8.75

During the past 4 years, the highest EV-to-Revenue of Panacea Life Sciences Holdings was 15.15. The lowest was 7.27. And the median was 10.66.

PLSH's EV-to-Revenue is ranked worse than
85.96% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.395 vs PLSH: 8.75

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-16), Panacea Life Sciences Holdings's stock price is $0.1384. Panacea Life Sciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.17. Therefore, Panacea Life Sciences Holdings's PS Ratio for today is 0.83.

Panacea Life Sciences Holdings EV-to-Revenue Historical Data

The historical data trend for Panacea Life Sciences Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings EV-to-Revenue Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

11.62

10.14

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial											12.74	15.15	13.80	10.14	9.18

Competitive Comparison of Panacea Life Sciences Holdings's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's EV-to-Revenue falls into.

Panacea Life Sciences Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Panacea Life Sciences Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	24.183	/	2.763
	=	8.75

Panacea Life Sciences Holdings's current Enterprise Value is $24.18 Mil.
Panacea Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.76 Mil.

Panacea Life Sciences Holdings (OTCPK:PLSH) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Panacea Life Sciences Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.1384	/	0.166
	=	0.83

Panacea Life Sciences Holdings's share price for today is $0.1384.
Panacea Life Sciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.

Panacea Life Sciences Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019